Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study

医学肝细胞癌肿瘤科血管内皮生长因子抗体酪氨酸激酶癌症研究免疫系统免疫检查点内科学免疫学免疫疗法血管内皮生长因子受体受体

作者

Zhicheng Jin,Jian-Jia Chen,Xiaoli Zhu,Xuhua Duan,Yujing Xin,Bin Zhong,Jinzhang Chen,Jun Tie,Kangshun Zhu,Lan Zhang,Ming Huang,Ming Guan Piao,Xiao Li,Haibin Shi,Rui-Bao Liu,Anjian Xu,Fanpu Ji,Jianbing Wu,Guoliang Shao,Hailiang Li,Mingsheng Huang,Zhangli Peng,Jiansong Ji,Chunwang Yuan,Xiufeng Liu,Zhiquan Hu,Yang Weizhu,Guowen Yin,Jinhua Huang,Naijian Ge,Xiaolong Qi,Yang Zhao,Jiawei Zhou,Gaixia Xu,Qiang Tu,Huilong Lin,Yaojun Zhang,Hua Jiang,Haibo Shao,Yu‐Jih Su,Tingsong Chen,Baoqi Shi,Xuechou Zhou,Hong Zhao,Hai‐Dong Zhu,Zhigang Ren,Gao‐Jun Teng,Zhicheng Jin,Jian-Jia Chen,Xiaoli Zhu,Xuhua Duan,Yujing Xin,Bin Zhong,Jinzhang Chen,Jun Tie,Kangshun Zhu,Lan Zhang,Ming Huang,Ming Guan Piao,Xiao Li,Haibin Shi,Rui-Bao Liu,Anjian Xu,Fanpu Ji,Jianbing Wu,Guoliang Shao,Hailiang Li,Mingsheng Huang,Zhangli Peng,Jiansong Ji,Chunwang Yuan,Xiufeng Liu,Zhiquan Hu,Yang Weizhu,Guowen Yin,Jinhua Huang,Naijian Ge,Xiaolong Qi,Yang Zhao,Jiawei Zhou,Gaixia Xu,Qiang Tu,Huilong Lin,Yaojun Zhang,Hua Jiang,Haibo Shao,Yu‐Jih Su,Tingsong Chen,Baoqi Shi,Wenge Xing,Shanzhi Gu,Weidong Wang,Song Wang,Shu-Wei Wen,Wenjing Lv,Zhu Xu,Wei Mu,Wei Ren,Zaiming Lu,Yong Fan,Jiaping Li,Weihua Zhao,Chuansheng Zheng,Xuya Zhao,Hui Zhao,Jingyi Xu,Wenhao Hu,Yanming Lei,Qinghua Wu,Huanzhang Niu,Jiarui Li,Jianjun Han,Dan Feng,Zheng Cai,Qingdong Li,Zhenyu Dai,Rong-Shu Shi,Yong Chen,Wenjun Wang,Lu Yin,Xuechou Zhou,Hong Zhao,Hai‐Dong Zhu,Zhigang Ren,Gao‐Jun Teng

出处

期刊：EClinicalMedicine [Elsevier]
日期：2024-06-01 卷期号：72: 102622-102622

链接

nih.govdoi.org

标识

DOI：10.1016/j.eclinm.2024.102622

摘要

The role of transarterial chemoembolization (TACE) in the treatment of advanced hepatocellular carcinoma (HCC) is unconfirmed. This study aimed to assess the efficacy and safety of immune checkpoint inhibitors (ICIs) plus anti-vascular endothelial growth factor (anti-VEGF) antibody/tyrosine kinase inhibitors (TKIs) with or without TACE as first-line treatment for advanced HCC.

求助该文献

最长约 10秒，即可获得该文献文件

Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study

今日热心研友